Malaria is still one of the most important tropical diseases, killing millions every year. The number of effective drugs is limited, because of the ability of the causative parasite Plasmodium falciparum to develop drug resistance. Mefloquine, if possible in combination with an artemisinin derivative, is the only efficacious treatment left for uncomplicated but highly multidrug-resistant P. falciparum infections encountered in some areas. Mefloquine remains effective in most endemic areas worldwide for both prophylaxis and treatment of malaria.
Generally, mefloquine is well tolerated but it is associated occasionally with neuropsychiatric adverse effects, whether used as treatment or for prophylaxis. In recent years, mefloquine has acquired a bad reputation mainly because of reports of neuropsychiatric reactions in travellers. These reports were widely publicised and amplified by the media. As a result, the confusion about recommendations for the prophylaxis of malaria has deepened and decisions on prophylactic regimens have been made that could have serious consequences. However, there is little evidence that the use of mefloquine should be avoided because of the risk of these adverse effects.
Although studies have shown that mefloquine is associated with neuropsychiatric adverse effects, most of these events have been mild and self-limiting. Some predisposing factors to the occurrence of neuropsychiatric adverse effects, such as a family history or a past history of neuropsychiatric disorders, recent (last 2 months) previous exposure to mefloquine or use of psychotropic drugs, were identified. Use of mefloquine should not be considered in these cases. Updated information about contraindications to mefloquine and the risk of malaria in areas visited should be available for medical professionals and patients.
All antimalarials have adverse effects; it is therefore essential to balance the risks and the benefits each time a malaria prophylaxis regimen is prescribed.
Malaria Adis International Limited Chloroquine Mefloquine Artesunate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Cook GC. Malaria prophylaxis. Mefloquine toxicity should limit its use to treatment alone [letter]. BMJ 1995; 311(6998): 190–1PubMedCrossRefGoogle Scholar
CIOMS International reporting of adverse drug reactions. CIOMS Working Group Report. Geneva: World Health Organization, 1997Google Scholar
World Health Organization. Review of central nervous system adverse events related to the antimalarial drug mefloquine (1985–1990). WHO/MAL/91.1063. Geneva: World Health Organization, 1991Google Scholar
Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341(8849): 848–51PubMedCrossRefGoogle Scholar
Hoebe C, de MJ, Thijs C. Side effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol 1997; 52(4): 269–75PubMedCrossRefGoogle Scholar
Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993; 341(8856): 1299–303PubMedCrossRefGoogle Scholar
Barrett PJ, Emmins PD, Clarke PD, et al. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 1996; 313(7056): 525–8PubMedCrossRefGoogle Scholar
Carme B, Peguet C, Nevez G. Compliance with and tolerance of mefloquine and chloroquine + proguanil malaria chemoprophylaxis in French short-term travellers to sub-Saharan Africa. Trop Med Int Health 1997; 2(10): 953–6PubMedCrossRefGoogle Scholar
Sanchez JL, DeFraites RF, Sharp TW, et al. Mefloquine or doxycycline prophylaxis in US troops in Somalia [letter]. Lancet 1993; 341(8851): 1021–2PubMedCrossRefGoogle Scholar
Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996; 42(4): 415–21PubMedCrossRefGoogle Scholar
Riemsdijk van RM, van der Klauw MM, van HJ, et al. Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997; 52(1): 1–6PubMedCrossRefGoogle Scholar
Croft AM, Clayton TC, World MJ. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 1997; 91(2): 199–203PubMedCrossRefGoogle Scholar
Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996; 1(4): 485–94PubMedCrossRefGoogle Scholar
Nosten F, Karbwang J, White NJ, et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol 1990; 30(1): 79–85PubMedCrossRefGoogle Scholar
Bunnag D, Malikul S, Chittamas S, et al. Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial. Southeast Asian J Trop Med Public Health 1992; 23 (4): 777–82PubMedGoogle Scholar
Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126(12): 963–72PubMedGoogle Scholar
Salako LA, Adio RA, Walker O, et al. Mefloquine-sulphadoxine-pyrimethamine (Fansimef, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled study. Ann Trop Med Parasitol 1992; 86(6): 575–81PubMedGoogle Scholar
Bern JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95(3): 167–79Google Scholar
Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993; 44(3): 257–65PubMedGoogle Scholar
Sturchler D, Handschin J, Kaiser D, et al. Neuropsychiatric side effects of mefloquine [letter]. N Engl J Med 1990; 322(24): 1752–3PubMedGoogle Scholar
Le NN, De VP, Le TD, et al. Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91(2): 191–4PubMedCrossRefGoogle Scholar
Behrens RH, Erny S, Maradit H, et al. Mefloquine to prevent malaria [letters]. BMJ 1998; 7149: 1980–1CrossRefGoogle Scholar
Hopperus Buma APCC, van Thiel PPAM, Lobel HO, et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996; 173: 1506–9PubMedCrossRefGoogle Scholar
Phillips-Howard PA, ter Kuile F. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf 1995; 12(6): 370–83PubMedCrossRefGoogle Scholar
Vuurman EF, Muntjewerff ND, Uiterwijk MM, et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996; 50(6): 475–82PubMedCrossRefGoogle Scholar
Wittes RC, Saginur R. Adverse reaction to mefloquine associated with ethanol ingestion. Can Med Assoc J 1995; 152(4): 515–7Google Scholar
Sowunmi A, Salako LA, Oduola AM, et al. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg 1993; 87(4): 462–3PubMedCrossRefGoogle Scholar
Luxemburger C, Nosten F, ter Kuile F, et al. Mefloquine for multidrug-resistant malaria [letter]. Lancet 1991; 338: 1268PubMedCrossRefGoogle Scholar
ter Kuile F. Mefloquine, halofantrine and artesunate in the treatment of uncomplicated falciparum malaria in a multidrug resistant area [PhD thesis]. Amsterdam: University of Amsterdam, 1994Google Scholar
Luxemburger C, Price RN, Nosten F, et al. Mefloquine in infants and young children. Ann Trop Paediatr 1996; 16(4): 281–6PubMedGoogle Scholar
McGready R, Cho T, Hkirijaroen L, et al. Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum in pregnancy. Ann Trop Med Parasit 1998; 92(6): 643–53PubMedCrossRefGoogle Scholar
Looareesuwan S, Wilairatana P, Molunto W, et al. A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand. Am J Trop Med Hyg 1997; 57(3): 348–53PubMedGoogle Scholar
Jones R, Kunsman G, Levine B, et al. Mefloquine distribution in postmortem cases. Forensic Sci Int 1994; 68(1): 29–32PubMedCrossRefGoogle Scholar
Pham YT, Nosten F, Farinotti R, et al. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol. In pressGoogle Scholar
Speich R, Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine [letter]. N Engl J Med 1994; 331 (1): 57–8PubMedCrossRefGoogle Scholar
Petersen E, Hogh B, Bygbjerg IC, et al. Malaria chemoprophylaxis: why mefloquine? [letter]. Lancet 1990; 336(8718): 811PubMedCrossRefGoogle Scholar
Behrens RH, Bradley DJ, Snow RW, et al. Impact of UK malaria prophylaxis policy on imported malaria [letter]. Lancet 1996; 348(9023): 344–5PubMedCrossRefGoogle Scholar